December 10, 2019
FDA to fast track Equillium’s itolizumab for lupus nephritis
Equillium got U.S. FDA’s Fast Track designation for itolizumab for the treatment of lupus nephritis, after startign the phase 1 study of itolizumab in patients with lupus and lupus nephritis in September 2019.
